For instance, in triple‐negative breast cancer, PRMT1 promotes paclitaxel resistance by methylating enzymes like PKM2 and PHGDH.[13] Similarly, PRMT1 has been implicated in acquired gemcitabine resistance in pancreatic cancer.[14] Despite these findings, the role of PRMT1 in chemotherapy resistance in HNSCC remains poorly understood. The gene discussed is PRMT1; the disease is pancreatic neoplasm.